The good news is - 180 researchers from 22 countries worked on a challenge called "Getting to Know Cancer" through a Canadian organization to create a detailed analysis of studies about the effects of plant substances. One team focused on chemical components in plants that prevent cancer growth through angiogenesis or blood flow to the active tumor.
“We lined up ten things that influence the blood vessel growth and pathological function of the tumour. I myself focused on physiological phenomena such as migration of endothelial cells, lack of oxygen, inflammation and inadequate lymphatic vessel function,” Mr Jensen said.
As you know at Second Nature, we focus on the lack of oxygen that allows inflammation and cancer cells to proliferate. We fight cancer with I.V. Ozone therapies, high dose plant-based oral nutraceuticals and chemical imprints of plants in injectable homeopathic nosodes.
The researchers identified more than 100 plant-based substances that worked on selected cancer targets and then compared the results to traditional chemotherapy. Oncologists give maximum toxic doses of chemotherapy which produce severe and permanent side effects. With plant-based substances - toxicity is low, plant chemicals are well-tolerated and these chemicals can synergize with other plant chemicals well to create a forceful life-affirming effect.
Some examples of plants that kill cancer studied are:
Reservatrol in grapes
Genistein in soybeans
Curcumin in turmeric
I did my medical school thesis on Mistletoe which is still manufactured in Switzerland by Weleda for different types of cancers. We offer injectable Mistletoe as Viscum Album.
We use many plants in your individualized cancer care protocol whether they are integrated into your diet, in injectable form in your I.V. bag or in oral nutraceutical form taken daily. Our broad-based approach works for our patients.
Article: Broad targeting of angiogenesis for cancer prevention and therapy by Z. Wang, C. Dabrosin, X. Yin, M. M. Fuster, A. Arreola, W. K. Rathmell, D. Generali, G. P. Nagaraju, B. El-Rayes, D. Ribatti, Y. C. Chen, K. Honoki, H. Fujii, A. G. Georgakilas, S. Nowsheen, A. Amedei, E. Niccolai, A. Amin, S. S. Ashraf, B. Helferich, X. Yang, G. Guha, D. Bhakta, M. R. Ciriolo, K. Aquilano, S. Chen, D. Halicka, S. I. Mohammed, A. S. Azmi, A. Bilsland, W. N. Keith, L. D. Jensen. Seminars in Cancer Biology, 18 November 2015, doi:10.1016/j.semcancer.2015.01.001